Sahdeo Prasad, Manoj K. Pandey, Vivek R. Yadav and Bharat ......Sahdeo Prasad, Manoj K. Pandey,...

Prasad et al 4/12/11 1

Gambogic Acid Inhibits STAT3 Phosphorylation Through

Activation of Protein Tyrosine Phosphatase SHP-1: Potential

Role in Proliferation and Apoptosis

Sahdeo Prasad, Manoj K. Pandey, Vivek R. Yadav and Bharat B. Aggarwal*

Cytokine Research Laboratory, Department of Experimental Therapeutics, The

University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

Running title: GA inhibits STAT3 activation pathway

Key words: Gambogic acid, STAT3, Apoptosis, Proliferation, Cancer

Address correspondence to: Bharat B. Aggarwal, The University of Texas MD Anderson

Cancer Center, 1515 Holcombe Blvd., Box 143, Houston, TX 77030. Phone: 713-794-

1817; Fax: 713-745-6339; E-mail: [email protected]

S. Prasad and M.K. Pandey contributed equally.

for Cancer Research. on September 5, 2018. © 2011 American Associationcancerpreventionresearch.aacrjournals.org Downloaded from

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 13, 2011; DOI: 10.1158/1940-6207.CAPR-10-0340





Retrac

ted Sep

tembe

r 4, 2

018

Cancer Research. on August 23, 2020. © 2011 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from






http://cancerpreventionresearch.aacrjournals.org/







Abstract

The transcription factor, signal transducer and activator of transcription 3 (STAT3), is

associated with proliferation, survival, and metastasis of cancer cells. We investigated

whether gambogic acid (GA), a xanthone derived from the resin of traditional Chinese

medicine, Gamboge hanburyi (mangosteen), can regulate the STAT3 pathway, leading to

suppression of growth and sensitization of cancer cells. We found that GA induced

apoptosis in human multiple myeloma cells that correlated with the inhibition of both

constitutive and inducible STAT3 activation. STAT3 phosphorylation at both tyrosine

residue 705 and serine residue 727 was inhibited by GA. STAT3 suppression was

mediated through the inhibition of activation of the protein tyrosine kinases Janus-

activated kinase (JAK) 1, and JAK2. Treatment with the protein tyrosine phosphatase

(PTP) inhibitor pervanadate reversed the GA-induced down-regulation of STAT3,

suggesting the involvement of a PTP. We also found that GA induced the expression of

the PTP SHP-1. Deletion of the SHP-1 gene by small interfering RNA suppressed the

ability of GA to inhibit STAT3 activation and to induce apoptosis, suggesting the critical

role of SHP-1 in its action. Moreover, GA down-regulated the expression of STAT3-

regulated antiapoptotic (Bcl-2, Bcl-xL, and Mcl-1), proliferative (cyclin D1), and

angiogenic (VEGF) proteins, and this correlated with suppression of proliferation and

induction of apoptosis. Overall, these results suggest that GA blocks STAT3 activation,

leading to suppression of tumor cell proliferation and induction of apoptosis.



Retrac

ted Sep

tembe

r 4, 2

018






Introduction

The successes of several recent clinical trials in preventing cancer in high-risk

populations suggest that chemoprevention is a rationale and appealing strategy.

Chemoprevention includes the use of natural or synthetic substances to reverse, suppress

or prevent the initiation, promotion, or progression of cancer. In particular, natural

compounds, which include fruits and vegetables, are important in the treatment of life-

threatening conditions. As many as 70% of all drugs discovered within the past 25 years

have their roots in natural products (1). Thus, there is growing interest in the possible

therapeutic potential of natural products against a variety of ailments. Moreover, almost

80% of the world population relies on natural products for their medical needs. Because

natural compounds are considered to be affordable and safe, many potential compounds

are now in different phases of clinical trials. Moreover, because cancer is a complex and

multigenic disease, agents that modulate multiple targets are preferred. Natural products,

because of their ability to bind multiple targets, thus have an advantage over rationally

designed mono-targeted agents.

One potentially useful natural compound is gambogic acid (GA; C38H44O8,

Fig. 1A), a xanthone derived from the resin of Garcinia hanburryi (also called

mangosteen), a plant that mainly grows in South China, Cambodia, Vietnam, and

Thailand (2). It has been shown that GA can suppress the growth of various cancer cells

such as non–small cell lung cancer cells (3), human hepatocellular carcinoma (4), oral

squamous cell carcinoma (5), human breast cancer cells (6), human malignant melanoma

(7), human gastric carcinoma (8), and human leukemia cancer cells (9). GA has also been

shown in animal models to inhibit the development of tumors (10, 11). A variety of



Retrac

ted Sep

tembe

r 4, 2

018






mechanisms have been proposed by which GA inhibits the proliferation of cancer cells

and induces apoptosis. These include inhibition of antiapoptotic proteins bcl-2 (6, 12) and

survivin (13); induction of apoptosis-associated proteins p53 (14), bax, and pro-caspase-3

(7); activation of c-Jun–N-terminal protein kinase (JNK), p38 (15) and glycogen synthase

kinase 3beta (GSK3beta) (16); inhibition of topoisomerase II by binding to its ATPase

domain (17), and NF-κB and its regulated gene products (9); down-regulation of the

MDM2 oncogene and subsequent induction of p21 (14); and down-regulation of hTERT

(10). It has also been shown to directly bind to c-myc (18), and transferrin receptors (19)

and to block vascular endothelial growth factor (VEGF) signaling (20, 21). Recently, a

proteomic approach revealed suppression of expression of 14-3-3 protein sigma and

stathmin by the GA (8).

Extensive research in the past few decades has revealed that most chronic

illnesses, including cancer, exhibit dysregulation of multiple cell signaling pathways. One

of the major signaling molecules in this regard is signal transducer and activator of

transcription (STAT)–3. The latter is transcription factor involved in cell proliferation,

differentiation, and apoptosis (22-24). STAT3 is constitutively active in many human

cancer cells, including multiple myeloma, leukemia, lymphoma, and solid tumors (25,

26). STAT3 can also be activated by certain interleukins (e.g., IL-6), growth factors (e.g.,

epidermal growth factor [EGF]), carcinogens and tumor promoters (27). The activation of

STAT3 is regulated by phosphorylation of tyrosine 705 by receptor and nonreceptor

protein tyrosine kinases such as EGF receptor (EGFR) kinase (28), Src (29), Janus-

activated kinase (JAK) (30, 31), and extracellular signal–regulated kinase (32). Upon



Retrac

ted Sep

tembe

r 4, 2

018






activation, STAT3 undergoes phosphorylation-induced homodimerization, leading to

nuclear translocation, DNA binding, and subsequent gene transcription.

Because of the critical role of STAT3 activation in tumor cell survival,

proliferation, and chemoresistance, we hypothesized that GA may mediate its effects

through suppression of the STAT3 pathway. We found that GA indeed suppressed both

constitutive and inducible STAT3 activation and down-regulated the expression of cell

survival, proliferative, and angiogenic gene products, leading to suppression of

proliferation and induction of apoptosis.

Material and Methods

Cell Lines. Human multiple myeloma lines U266, MM.1S (melphalan-sensitive) and

MM.1R (melphalan-resistant), head and neck squamous cell carcinoma SCC4, prostate

cancer PC-3 and DU145, and breast cancer MCF-7 cells were obtained from the

American Type Culture Collection. MCF-10A cells were kindly provided by Dr. Kapil

Mehta from our Institute. U266 (ATCC TIB-196) is a plasmacytoma of B-cell origin and

is known to produce monoclonal antibodies and IL-6. MM.1S cell line, established from

the peripheral blood cells of a patient with IgA myeloma, secretes EL chain, is negative

for the presence of the Epstein-Barr virus genome, and expresses leukocyte antigen DR,

plasma cell Ag-1, and T9 and T10 antigens. U266, MM.1S, and MM.1R cells were

cultured in RPMI 1640 containing 10% fetal bovine serum (FBS). SCC4 cells were

cultured in DMEM containing 10% FBS, nonessential amino acids, pyruvate, glutamine,

and vitamins. All media were also supplemented with 100 units/mL of penicillin and 100

μg/mL of streptomycin. The above-mentioned cell lines were procured more than 6



Retrac

ted Sep

tembe

r 4, 2

018






months ago and have not been tested recently for authentication in our laboratory.

Reagents. GA was obtained from Alexis Laboratories (San Diego, CA). A 10 mM

solution of GA was prepared in dimethyl sulfoxide, stored as small aliquots at -20°C, and

then diluted as needed in cell culture medium. Hoechst 33342, MTT, Tris, glycine, NaCl,

SDS, and bovine serum albumin were purchased from Sigma-Aldrich (St. Louis, MO).

RPMI 1640, FBS, 0.4% trypan blue vital stain, and antibiotic-antimycotic mixture were

obtained from Invitrogen (Carlsbad, CA). Rabbit polyclonal antibodies to STAT3 and

mouse monoclonal antibodies against phospho-STAT3 (Tyr705), phospho-STAT3

(Ser727), phospho-JAK1 (Tyr1022/1023), JAK1, phospho-JAK2 (Tyr1007/1008), and

JAK2, Bcl-2, Bcl-xL, Mcl-1, SHP-1, cyclin D1, procaspase-3, -9, and poly(ADP-ribose)

polymerase were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-

mouse horseradish peroxidase was purchased from Transduction Laboratories (Lexington,

KY), and goat anti-rabbit Alexa Fluor 594 was purchased from Invitrogen. Bacteria-

derived recombinant human IL-6 was kindly provided by Novartis Pharmaceuticals (East

Hanover, NJ). The siRNA for SHP-1, and the scrambled control were obtained from

Ambion (Austin, TX). GST-JAK2 substrate was kindly provided by Dr. Zhizhuang Joe

Zhao (Department of Pathology, University of Oklahoma Health Sciences Center,

Oklahoma City, OK).

Propidium Iodide (PI) Staining for Apoptosis. Cells were pretreated with GA (2.5 μM)

for different times. PI staining for cell distribution across the cell cycle was performed

with a FACSCalibur device (Becton Dickinson, Bedford, MA) as described elsewhere



Retrac

ted Sep

tembe

r 4, 2

018






(33). A total of 10,000 events were analyzed by flow cytometry using an excitation

wavelength set at 488 nm and emission set at 610 nm.

Annexin V/PI Assay. An early indicator of apoptosis is the rapid translocation and

accumulation of the membrane phospholipid phosphatidylserine from the cytoplasmic

interface of membrane to the extracellular surface. This loss of membrane asymmetry can

be detected by using the binding properties of annexin V. To identify apoptosis, we used

an annexin V antibody, which was conjugated with a fluorescein isothiocyanate (FITC)

fluorescent dye. Briefly, 2 x 106 cells were pretreated with GA for different times at 37°C

and subjected to annexin V staining. The cells were washed in PBS, resuspended in 100

µL of binding buffer containing an FITC-conjugated anti–annexin V antibody, and then

analyzed with a flow cytometer (FACSCalibur, BD Biosciences).

Live/Dead Assay. To measure apoptosis, we used the Live/Dead Assay (Invitrogen),

which assesses intracellular esterase activity and plasma membrane integrity. This assay

was performed as described previously (33).

Cytotoxicity assay. The cytotoxic effects of gambogic acid were determined by the 3-

(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) uptake method (9).

Western Blot Analysis. To detect various proteins, cells treated with GA were washed

with PBS and protein extracted by incubation for 30 min on ice in lysis buffer containing

20 mM HEPES (pH 7.4), 2 mM ethylenediaminetetraacetic acid, 250 mM NaCl, 0.1%



Retrac

ted Sep

tembe

r 4, 2

018






NP-40, 2 μg /mL leupeptin, 2 μg/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.5

μg/mL benzamidine, 1 mM dithiothreitol (DTT), and 1 mM sodium vanadate. The lysate

was centrifuged, and the supernatant was collected. Whole-cell extract protein (40 μg)

was resolved on 7.5%–12% SDS-polyacrylamide gel electrophoresis (PAGE),

electrotransferred onto a nitrocellulose membrane, blotted with antibodies, and then

detected by electrochemiluminescence (Amersham Biosciences).

Immunocytochemistry for STAT3 Localization. GA-treated cells were plated on a

glass slide by centrifugation using a Cytospin 4 (Thermoshendon, Pittsburg, PA), air-

dried for 1 h at room temperature, and fixed in 4% formaldehyde. After a brief washing

in PBS, slides were blocked with 5% normal goat serum for 1 h and then incubated with

rabbit polyclonal anti-human STAT3 antibody (dilution, 1:100). After overnight

incubation, the slides were washed and then incubated with goat anti-rabbit IgG-Alexa

594 (1:100) for 1 h and counterstained for nuclei with Hoechst (50 ng/ml) for 5 min.

Stained slides were mounted with mounting medium and analyzed under an

epifluorescence microscope (Labophot- 2; Nikon, Tokyo, Japan). Pictures were captured

using a Photometrics Coolsnap CF color camera (Nikon) and MetaMorph version 4.6.5

software (Molecular Devices, Sunnyvale, CA).

Electrophoretic Mobility Shift Assay for STAT3-DNA Binding. STAT3-DNA binding

was analyzed by electrophoretic mobility shift assay (EMSA) using a 32P-labeled high-

affinity sis-inducible element (hSIE) probe (forward, 5’-

CTTCATTTCCCGTAAATCCCTAAAGCT-3’ and reverse 5’-



Retrac

ted Sep

tembe

r 4, 2

018






AGCTTTAGGGATTTACGGGAAATGA-3’) as previously described (33). Briefly,

nuclear extracts were prepared from GA-treated cells and incubated with the hSIE probe.

The DNA-protein complex formed was separated from free oligonucleotide on 5% native

polyacrylamide gels. The dried gels were visualized, and the radioactive bands were

quantitated with a Storm 820 and Imagequant software (Amersham).

Transfection with siRNA. SCC4 cells were plated in each well of 6-well plates and

allowed to adhere for 24 h. On the day of transfection, 12 μL of HiPerFect transfection

reagent (QIAGEN) was added to 50 nM SHP-1 siRNA in a final volume of 100 μL of

culture medium. After 48 h of transfection, cells were treated with GA for 24 h. Cells

were used for the live/dead assay and Western blotting of SHP-1.

Kinase Assay. To determine the effect of GA on JAK2 activation, we performed an

immunocomplex kinase assay using GST-JAK2 as the substrate, as described previously

(33). In brief, the JAK complex from whole-cell extracts was precipitated with antibody

against JAK2 and treated with protein A/G-agarose beads (Pierce, Rockford, IL). After 2

h, the beads were washed with whole-cell extract buffer and then resuspended in a kinase

assay mixture containing 50 mM HEPES (pH 7.4), 20 mM MgCl2, 2 mM dithiothreitol,

20 μCi [γ-32P]ATP, 10 μM unlabeled ATP, and 2 μg of substrate GST-JAK2. After

incubation at 30°C for 30 min, the reaction was terminated by boiling with SDS sample

buffer for 5 min. Finally, the protein was resolved on 10% SDS-PAGE, the gel was dried,

and the radioactive bands were visualized with the Storm 820 imaging system. To

determine the total amounts of JAK2 in each sample, 40 μg of whole-cell proteins was



Retrac

ted Sep

tembe

r 4, 2

018






resolved on 10% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and then

blotted with anti-JAK2 antibody.

Results

The goal of this study was to determine whether GA can inhibit the STAT3 cell signaling

pathway, leading to suppression of proliferation and induce apoptosis. We investigated

the effect of GA on both constitutive and IL-6-inducible STAT3 activation. Whether GA

affects STAT3-regulated gene products involved in cellular proliferation, survival, and

apoptosis was also investigated.

GA Induces Apoptosis in multiple myeloma cells. We first examined the apoptosis-

inducing effects of GA using the annexin V/PI assay, which detects phosphatidylserine

externalization. For this, human multiple myeloma U266 cells were exposed to a 2.5µM

concentration of GA for different times. GA significantly induced apoptosis in time-

dependent manner (Fig. 1B, left panel).

To confirm the GA-induced cell death, we also measured apoptosis by propidium

iodide staining of DNA. We found that GA induced apoptosis from 1% in control cells to

30% in GA-treated cells within 24 h (Fig. 1B, right panel).

We also measured apoptosis by intracellular esterase activity and plasma

membrane integrity using the live/dead assay. The results indicated that GA treatment

induced apoptosis from 2% in control cells to 65% in GA-treated cells within 24 h (Fig.

1C).



Retrac

ted Sep

tembe

r 4, 2

018






Next, we examined the effect of GA on the activation of caspase-9, caspase-3 and

poly(ADP-ribose) polymerase (PARP) cleavage. We found that GA cleaved procaspase-9

and procaspase-3, leading to the appearance of caspase-9 and caspase-3 respectively, in a

time-dependent manner. We also found that GA induced PARP cleavage in time-

dependent manner (Fig. 1D, left panel). Taken together, all these results suggest that GA

can induce apoptosis in human multiple myeloma cells.

To determine whether GA is selectively more cytotoxic to tumor cells than

normal cells, we employed human breast cancer MCF-7 and human normal counterpart

MCF-10A cells. Under the conditions when GA induced 75% cytotoxicity in MCF-7

cells, only 13% cytotoxicity was observed in MCF-10A cells. These results thus indicate

that GA is highly cytotoxic to tumor cells (Fig. 1D, right panel).

GA Inhibits Constitutive STAT3 Phosphorylation in Multiple Myeloma Cells. We

investigated whether GA modulates constitutive STAT3 activation in multiple myeloma

cells. We incubated U266 cells with different concentrations of GA for 6 h and examined

them for phosphorylated STAT3 by Western blot analysis using an antibody that

recognizes STAT3 phosphorylated at the tyrosine 705 site. As shown in Figure 2A), GA

inhibited constitutive STAT3 activation in the U266 cells, with maximum inhibition

occurring at 2.5 μM GA. GA had no effect on STAT3 protein expression.

We also determined the effect of GA incubation time required to suppress STAT3

activation in U266 cells. As shown in Figure 2B, STAT3 inhibition was time-dependent,

with maximum inhibition occurring 6 h after the beginning of GA treatment. Interestingly,



Retrac

ted Sep

tembe

r 4, 2

018






GA also inhibited STAT3 phosphorylated at serine 727 site (Fig. 2B). Under these

conditions, GA had no significant effects on cell viability.

GA Suppresses the Nuclear Translocation of STAT3. Because tyrosine

phosphorylation causes dimerization of STATs and then nuclear translocation, whether

GA inhibited nuclear translocation of STAT3 was examined in U266 cells by

immunocytochemistry. Our results showed that GA was able to inhibit the nuclear

translocation of STAT3 (Fig. 2C).

GA Inhibits Binding of STAT3 to the DNA. When STAT3 is translocated to the

nucleus, it binds to the DNA, an event that in turn regulates gene transcription. Whether

GA inhibits DNA binding activity of STAT3 was examined by EMSA. Nuclear extracts

prepared from U266 cells showed STAT3 DNA-binding activity and that GA inhibited

this binding in a dose-dependent (Fig. 2D, left panel) and time-dependent (Fig. 2D, right

panel) manner. No loss of cell viability was noted under these conditions.

GA Inhibits IL-6–Induced STAT3 Phosphorylation. Because IL-6 is a growth factor

for multiple myeloma cells and induces STAT3 phosphorylation, we determined whether

GA could inhibit IL-6–induced STAT3 phosphorylation. Multiple myeloma cells, which

lack constitutively active STAT3, were treated with IL-6 for different times and then

examined for phosphorylated STAT3. IL-6 induced phosphorylation of STAT3 as early

as 15 min, but phosphorylation began to decline at 60 min (Fig. 3A). In multiple



Retrac

ted Sep

tembe

r 4, 2

018






myeloma cells pretreated with GA for 6 h, IL-6–induced STAT3 phosphorylation was

suppressed (Fig. 3B).

GA Suppresses the Constitutive Activation of JAK1 and JAK2. STAT3 has been

reported to be activated by soluble tyrosine kinases of the JAK family; thus, we sought to

determine whether GA affects the constitutive activation of JAK1 in U266 cells. We

found that GA suppressed the constitutive phosphorylation of JAK1 (Fig. 4A). Levels of

nonphosphorylated JAK1 remained unchanged under the same conditions.

To determine the effect of GA on JAK2 activation, GA-treated cells were used for

Western blot with the anti–phospho-JAK2 antibody. As shown in Fig. 4B, JAK2 was

constitutively active in U266 cells and pretreatment with GA suppressed this

phosphorylation in a time-dependent manner.

We further investigated whether GA affects JAK2 activity in U266 cells using

immunocomplex kinase assays with GST-JAK2 acting as the substrate. We found that

GA suppressed the constitutive facilitation of JAK2 in a time-dependent manner (Fig.

4C).

GA-Induced Inhibition of STAT3 Activation Involves a Protein Tyrosine

Phosphatase. Because protein tyrosine phosphatases have been implicated in STAT3

activation, we determined whether GA-induced inhibition of STAT3 tyrosine

phosphorylation could be due to the activation of a protein tyrosine phosphatase (PTPase).

Treatment of U266 cells with the broad-acting tyrosine phosphatase inhibitor sodium

pervanadate prevented the GA-induced inhibition of STAT3 activation (Fig. 5A). This



Retrac

ted Sep

tembe

r 4, 2

018






suggests that tyrosine phosphatases are involved in the GA-induced inhibition of STAT3

activation.

GA Induces SHP-1 Expression in U266 Cells. SHP-1 is a nontransmembrane PTPase

expressed most abundantly in hematopoietic cells (34). PTPases have been shown to be

involved in the negative regulation of JAK/STAT signaling in leukemia and lymphoma.

Therefore, we examined whether GA modulates SHP-1 expression in U266 cells. We

incubated cells with GA for various times. As shown in (Fig. 5B), GA induced SHP-1

protein expression in U266 cells. Our results suggest that the stimulation of SHP-1

expression by GA could be associated with the down-regulation of constitutive STAT3

activation in U266 cells.

Gene Silencing of SHP-1 Reverses the Effect of GA on STAT3. We determined

whether the suppression of SHP-1 expression by siRNA would abrogate the inhibitory

effect of GA on STAT3 activation. Western blotting showed that GA-induced SHP-1

expression was effectively abolished in the cells treated with SHP-1 siRNA; treatment

with scrambled siRNA had no effect (Fig. 5C; left panel). We also found that GA failed

to suppress STAT3 activation in cells treated with SHP-1 siRNA (Fig. 5C; right panel).

These results suggest the critical role of SHP-1 in the suppression of STAT3

phosphorylation by GA.

Gene Silencing of SHP-1 Reduces GA-Induced Apoptosis. We showed above that

SHP-1 plays a critical role in the suppression of STAT-3 phosphorylation by GA.



Retrac

ted Sep

tembe

r 4, 2

018






Whether SHP-1 siRNA also affects GA-induced apoptosis was determined. We found

that knockdown of SHP-1 significantly decreased the apoptotic effects of GA (Fig. 5D).

By contrast, treatment with control siRNA had no effect (Fig. 5D).

GA Down-Regulates the Expression of Antiapoptotic Proteins. STAT3 has been

shown to regulate the expression of various gene products involved in proliferation and

cell survival (22, 23); thus, whether down-regulation of STAT3 activation by GA leads to

down-regulation of these gene products was examined. The results showed that GA

inhibited the expression of c-IAP, survivin, Mcl-1, bcl-2 and bcl-xl in a time-dependent

manner. The inhibition was less pronounced for bcl-2 than for the other gene products.

Maximum suppression was observed at around 12–24 h (Fig. 6A).

GA Suppresses the Expression of Proliferative Proteins. Cyclin D1, which is required

for cell proliferation and for transition from the G1 to S phase of the cell cycle, is also

regulated by STAT3. We therefore examined the effect of GA on constitutive expression

of cyclin D1 in U266 cells. Our results showed that GA treatment suppressed the

expression of cyclin D1 in a time-dependent manner (Fig. 6B).

GA Down-Regulates the Expression of Angiogenic Proteins. VEGF, a major mediator

of angiogenesis, is regulated by STAT3 activation. Therefore, we examined the effect of

GA on constitutive VEGF expression in U266 cells. Our results show that GA inhibited

the expression of this protein in U266 cells in a time-dependent manner (Fig. 6B).



Retrac

ted Sep

tembe

r 4, 2

018






Discussion

Because STAT3 activation has been linked with most chronic diseases, including cancer,

our findings that GA modulates the STAT3 cell signaling pathway provide a rationale for

its use to treat various types of cancer. We demonstrate that GA was effective in blocking

the activation of the STAT3 pathway. It suppressed both constitutive and inducible

activation of STAT3. This inhibition was linked to the down-regulated activation of

various kinases linked to STAT3 activation and induction of phosphatases. Down-

regulation of STAT3 activation led to the suppression of expression of various proteins

involved in the survival and proliferation of tumor cells (Fig. 6C).

We investigated in detail how GA induces apoptosis. First, we found that GA

inhibited the phosphorylation of STAT3 at both tyrosine residue 705 and serine residue

727. Although the role of tyrosine 705 in STAT3 activation is well known (22). PKC,

MAPK, and CDK5 have been implicated in the phosphorylation of STAT3 at serine 727

(22). PKC- ε has been shown to interact with STAT3 directly and phosphorylate serine

727 (35). Whether GA affects any of these kinases is not clear at present. Similarly, a

large number of tyrosine kinases have been linked to phosphorylation of STAT3. These

include EGFR (36), JAK1 and JAK2 (30, 31), and c-Src (29). We found that GA

inhibited c-Src, JAK1, and JAK2 activation. C-Src–mediated STAT3 activation has been

linked to the transformation of cells. Various tumors exhibit persistently active STAT3

that is associated with activated Src, including breast cancer (37), and melanoma (38).

Inhibition of Src in these tumors by GA should down-regulate STAT3 activation and

suppress growth.



Retrac

ted Sep

tembe

r 4, 2

018






We also found evidence that inhibition of STAT3 activation is linked to the

induction of a PTP by GA. Numerous PTPs have been implicated in STAT3 signaling,

including SHP-1 (39), SHP-2 (40), TC-PTP (41), PTEN (42), PTP-1D (43), CD45 (43),

and PTP-ε. We found that GA inhibits the STAT3 activation pathway through the

induction of SHP1. GA was found to stimulate the expression of SHP-1 protein in U266

cells, which correlated with down-the regulation of constitutive STAT3 phosphorylation

in these cells. Silencing of the SHP-1 gene by siRNA reversed the STAT3 inhibitory

effect of GA, thereby further implicating a critical role of this phosphatase in GA-induced

down-regulation of STAT3 activation. The silencing the SHP1 also reversed GA-induced

apoptosis. Loss of SHP-1 has been shown to enhance JAK3/STAT3 signaling in

anaplastic lymphoma kinase–positive anaplastic large-cell lymphoma (39). SHP-1 has

been shown to be inactive in various human tumors, including multiple myeloma (44)

and lymphoma (39). DNA methylation has been described as one of the mechanisms for

inactivation of SHP-1 in different cancers (44).

Previously, we showed that GA can also suppress NF-κB activation (9). Whether

the suppression of STAT3 activation by GA is also linked to the inhibition of NF-κB

activation is not clear. The p65 subunit of NF-κB has been shown to interact with STAT3

(45). STAT3 and NF-κB, however, are activated in response to different cytokines: IL-6

is a major activator of STAT3 and tumor necrosis factor is a potent activator of NF-κB.

Interestingly, erythropoietin has been shown to activate NF-κB through the activation of

JAK2 kinase (46). Thus, it is possible that the suppression of JAK2 kinase activation is

the critical target for the inhibition of both NF-κB and STAT3 activation by GA.

We also found that GA suppresses the expression of STAT3-regulated proteins,



Retrac

ted Sep

tembe

r 4, 2

018






including cell proliferative cyclin D1, COX-2, the angiogenic protein VEGF, and

antiapoptotic gene products, including c-IAP, Mcl-1, survivin, bcl-2, and bcl-xL.

However, no appreciable change was observed in the expression of ICAM-1 by GA

treatment. Amongst the many genes controlled by NF-κB and STAT3, either

synergistically or individually. Some genes are prominent targets for both NF-κB and

STAT3, such as Bcl-xL, Bcl-2, c-IAP, cyclin D1, VEGF, COX-2 whereas A1 and c-FLIP

are mostly NF-κB-dependent and Mcl-1 and survivin are STAT3-dependent (22, 45, 47,

48). The down-regulation of bcl-2 and survivin by GA that we found is in agreement with

previous reports (12, 13). Expression of Bcl-xL has been reported to be regulated by

STAT3 (38), and it is overexpressed in multiple myeloma cells (49). Bcl-xL has also

been shown to block cell death induced by a variety of chemotherapeutic agents, in

parallel with an increase in chemoresistance. The down-regulation of Bcl-xL expression

that we found is likely linked to the ability of GA to induce apoptosis in multiple

myeloma cells. The down-regulation of Bcl-2, Bcl-xL, and survivin expression is likely

linked to the ability of GA to induce apoptosis in multiple myeloma cells. We further

observed that GA induced the down-regulation of Mcl-1 protein. Because VEGF

expression is also regulated by STAT3, GA may mediate antiangiogenesis through the

down-regulation of VEGF. We and others have indeed shown that GA can suppress

angiogenesis (9, 20, 21).

Constitutive STAT3 activation is associated with various types of carcinoma,

sarcoma, lymphoma, and leukemia (23). Thus, the suppression of constitutively active

STAT3 in multiple myeloma cells raises the possibility that GA might also inhibit

constitutively active STAT3 in other types of cancer cells (22). We observed that GA



Retrac

ted Sep

tembe

r 4, 2

018






inhibited the growth of head and neck cancer, breast carcinoma, and human prostate

carcinoma cells.

Perhaps one of the best in vitro model of premalignancy for cancer prevention is

STAT3 as suggested by the evidence, first that STAT3 plays a major role in oncogenesis

and regarded as an oncogene (50-52); second, STAT3 is activated by an oncogenic Src

(29, 50); third, STAT3 regulates transformation, inflammation, survival, proliferation and

angiogenesis of the tumors through expression of c-myc, COX2, bcl-xl, survivin, cyclin

D1 and VEGF respectively (53-56). Because our evidences indicate that gambogic acid

downregulates STAT3 activation and STAT3-regulated gene expression, it suggests

chemopreventive role of gambogic acid in an in vitro premalignancy model of cancer

prevention. Overall, our results show that GA inhibits growth and induces apoptosis in

various tumor cells through suppression of both inducible and constitutive STAT3

activation via the induction of tyrosine kinase phosphatase. Further studies in animals are

needed to validate human clinical trials. Moreover, in China, this agent is already in

clinical trials (13).

Acknowledgement

We thank Virginia M. Mohlere for carefully editing the manuscript. Dr. Aggarwal is the

Ransom Horne, Jr., Professor of Cancer Research. This work was supported by a grant

from the Clayton Foundation for Research (B.B.A.), a core grant from the National

Institutes of Health (CA-106672), a program project grant from National Institutes of

Health (NIH CA-124787-01A2), and a grant from Center for Targeted Therapy of MD

Anderson Cancer Center.



Retrac

ted Sep

tembe

r 4, 2

018






References

1. Newman DJ. Natural products as leads to potential drugs: an old process or the new

hope for drug discovery? J Med Chem 2008; 51: 2589-99.

2. Yang QZ, Jia SJ, DH L. The neoteric study of chinese traditional drug, gamboge. .

Chin J Clin Oncol 1994; 21: 464-5.

3. Zhu X, Zhang H, Lin Y, et al. Mechanisms of gambogic acid-induced apoptosis in

non-small cell lung cancer cells in relation to transferrin receptors. J Chemother 2009;

21: 666-72.

4. Mu R, Lu N, Wang J, et al. An oxidative analogue of gambogic acid-induced

apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its

anticancer activity in vitro. Eur J Cancer Prev 2010; 19: 61-7.

5. He D, Xu Q, Yan M, et al. The NF-kappa B inhibitor, celastrol, could enhance the

anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer

2009; 9: 343.

6. Gu H, Rao S, Zhao J, et al. Gambogic acid reduced bcl-2 expression via p53 in

human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 2009; 135: 1777-82.

7. Xu X, Liu Y, Wang L, et al. Gambogic acid induces apoptosis by regulating the

expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant

melanoma A375 cells. Int J Dermatol 2009; 48: 186-92.

8. Wang X, Chen Y, Han QB, et al. Proteomic identification of molecular targets of

gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics 2009; 9:

242-53.



Retrac

ted Sep

tembe

r 4, 2

018






9. Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB.

Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced

apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood

2007; 110: 3517-25.

10. Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of

human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase

activity and telomerase reverse transcriptase mRNA expression in the cells. Biol

Pharm Bull 2004; 27: 1769-74.

11. Gu H, You Q, Liu W, et al. Gambogic acid induced tumor cell apoptosis by T

lymphocyte activation in H22 transplanted mice. Int Immunopharmacol 2008; 8:

1493-502.

12. Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Gambogic acid induces apoptosis and

regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803

cells. Biol Pharm Bull 2004; 27: 998-1003.

13. Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B. Gambogic acid, a potent inhibitor of

survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett 2008; 262:

214-22.

14. Rong JJ, Hu R, Song XM, et al. Gambogic acid triggers DNA damage signaling that

induces p53/p21(Waf1/CIP1) activation through the ATR-Chk1 pathway. Cancer Lett

2010; 296: 55-64.

15. Chen J, Gu HY, Lu N, et al. Microtubule depolymerization and phosphorylation of c-

Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle



Retrac

ted Sep

tembe

r 4, 2

018






arrest and apoptosis in human breast carcinoma MCF-7 cells. Life Sci 2008; 83: 103-

9.

16. Li R, Chen Y, Zeng LL, et al. Gambogic acid induces G0/G1 arrest and apoptosis

involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia

cells. Toxicology 2009; 262: 98-105.

17. Qin Y, Meng L, Hu C, et al. Gambogic acid inhibits the catalytic activity of human

topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 2007; 6:

2429-40.

18. Yu J, Guo QL, You QD, et al. Repression of telomerase reverse transcriptase mRNA

and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer

Chemother Pharmacol 2006; 58: 434-43.

19. Kasibhatla S, Jessen KA, Maliartchouk S, et al. A role for transferrin receptor in

triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci U S A

2005; 102: 12095-100.

20. Lu N, Yang Y, You QD, et al. Gambogic acid inhibits angiogenesis through

suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of

KDR/Flk-1. Cancer Lett 2007; 258: 80-9.

21. Yi T, Yi Z, Cho SG, et al. Gambogic acid inhibits angiogenesis and prostate tumor

growth by suppressing vascular endothelial growth factor receptor 2 signaling.

Cancer Res 2008; 68: 1843-50.

22. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and

activator of transcription-3, inflammation, and cancer: how intimate is the

relationship? Ann N Y Acad Sci 2009; 1171: 59-76.



Retrac

ted Sep

tembe

r 4, 2

018






23. Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducer-and-activator-of-

transcription-3 for prevention and therapy of cancer: modern target but ancient

solution. Ann N Y Acad Sci 2006; 1091: 151-69.

24. Ihle JN. Cytokine receptor signalling. Nature 1995; 377: 591-4.

25. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits

constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma

cells. J Immunol 2003; 171: 3863-71.

26. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides

novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-

54.

27. Tharappel JC, Lee EY, Robertson LW, Spear BT, Glauert HP. Regulation of cell

proliferation, apoptosis, and transcription factor activities during the promotion of

liver carcinogenesis by polychlorinated biphenyls. Toxicol Appl Pharmacol 2002;

179: 172-84.

28. Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts

transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth

Differ 1997; 8: 1267-76.

29. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-

related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-3.

30. Lutticken C, Wegenka UM, Yuan J, et al. Association of transcription factor APRF

and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994;

263: 89-92.



Retrac

ted Sep

tembe

r 4, 2

018






31. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in

T cells transformed with HTLV-I. Science 1995; 269: 79-81.

32. Megeney LA, Perry RL, LeCouter JE, Rudnicki MA. bFGF and LIF signaling

activates STAT3 in proliferating myoblasts. Dev Genet 1996; 19: 139-45.

33. Pandey MK, Sung B, Aggarwal BB. Betulinic acid suppresses STAT3 activation

pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple

myeloma cells. Int J Cancer 2010; 127: 282-92.

34. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase

SHP-1 in cancer. Gene 2003; 306: 1-12.

35. Aziz MH, Manoharan HT, Church DR, et al. Protein kinase Cepsilon interacts with

signal transducers and activators of transcription 3 (Stat3), phosphorylates

Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res

2007; 67: 8828-38.

36. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. EGFR

dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 2001;

19: 1155-60.

37. Diaz N, Minton S, Cox C, et al. Activation of stat3 in primary tumors from high-risk

breast cancer patients is associated with elevated levels of activated SRC and survivin

expression. Clin Cancer Res 2006; 12: 20-8.

38. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in

melanoma tumor cell growth. Oncogene 2002; 21: 7001-10.



Retrac

ted Sep

tembe

r 4, 2

018






39. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances

JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-

ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006; 108: 2796-803.

40. Kim H, Hawley TS, Hawley RG, Baumann H. Protein tyrosine phosphatase 2 (SHP-

2) moderates signaling by gp130 but is not required for the induction of acute-phase

plasma protein genes in hepatic cells. Mol Cell Biol 1998; 18: 1525-33.

41. Yamamoto T, Sekine Y, Kashima K, et al. The nuclear isoform of protein-tyrosine

phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through

STAT3 dephosphorylation. Biochem Biophys Res Commun 2002; 297: 811-7.

42. Sun S, Steinberg BM. PTEN is a negative regulator of STAT3 activation in human

papillomavirus-infected cells. J Gen Virol 2002; 83: 1651-8.

43. Gunaje JJ, Bhat GJ. Involvement of tyrosine phosphatase PTP1D in the inhibition of

interleukin-6-induced Stat3 signaling by alpha-thrombin. Biochem Biophys Res

Commun 2001; 288: 252-7.

44. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1

hypermethylation in multiple myeloma: implications for epigenetic activation of the

Jak/STAT pathway. Blood 2004; 103: 4630-5.

45. Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3

(STAT3) inhibits transcription of the inducible nitric oxide synthase gene by

interacting with nuclear factor kappaB. Biochem J 2002; 367: 97-105.

46. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves

cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001; 412: 641-

7.



Retrac

ted Sep

tembe

r 4, 2

018






47. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;

3: 221-7.

48. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration

and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-9.

49. Peeters SD, Hovenga S, Rosati S, Vellenga E. Bcl-xl expression in multiple

myeloma. Med Oncol 2005; 22: 183-90.

50. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;

98: 295-303.

51. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:

2474-88.

52. Pedranzini L, Leitch A, Bromberg J. Stat3 is required for the development of skin

cancer. J Clin Invest 2004; 114: 619-22.

53. Vultur A, Arulanandam R, Turkson J, Niu G, Jove R, Raptis L. Stat3 is required for

full neoplastic transformation by the Simian Virus 40 large tumor antigen. Mol Biol

Cell 2005; 16: 3832-46.

54. Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is

required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci

U S A 2001; 98: 7319-24.

55. Gritsko T, Williams A, Turkson J, et al. Persistent activation of stat3 signaling

induces survivin gene expression and confers resistance to apoptosis in human breast

cancer cells. Clin Cancer Res 2006; 12: 11-9.

56. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF

expression and tumor angiogenesis. Oncogene 2002; 21: 2000-8.



Retrac

ted Sep

tembe

r 4, 2

018






Legend of figures

Figure 1. Effects of GA in induction of apoptosis in multiple myeloma cells. (A)

Chemical structure of GA. (B) GA-induced apoptosis. U266 cells were treated with GA

(2.5 μM) for indicated times, and cell death was determined by fluorescence-activated

cell sorting using annexin V/propidium iodide staining (left panel) and propidium iodide

staining (right panel). (C) GA (2.5 μM) induced cell death treated for indicated times as

determined by the live/dead assay. (D) Cleavage of procaspase-9, -3 and poly(ADP

ribose) polymerase as determined by Western blotting in whole-cell extracts of GA-

treated cells. The same blot was stripped and reprobed with STAT3 antibody to verify

equal protein loading (left panel). MCF-7 and MCF-10A cells were pretreated with

indicated concentration of GA for 24 h. Cell viability was then analyzed by the MTT

method (right panel).

Figure 2. (A) GA suppresses constitutive expression of phospho-STAT3. U266 (2x106

cells/mL) were treated with the indicated concentrations of GA for 6 h, after which

whole-cell extracts were prepared, and 40 µg of protein were resolved on 10% SDS-

PAGE gel, electrotransferred onto nitrocellulose membranes, and probed for phospho-

STAT3 (Tyr705). The same blots were stripped and reprobed with STAT3 antibody to

verify equal protein loading. (B) GA suppresses STAT3 phosphorylated at tyrosine705

and serine727 in a time-dependent manner. U266 cells (2 x106/mL) were treated with the

2.5 µM GA for the indicated times, after which Western blotting was performed for

phospho-STAT3 (Tyr705) as described previously. The same blots were stripped and

reprobed with phospho STAT-3 (Ser727) and then STAT3 to verify equal protein loading.



Retrac

ted Sep

tembe

r 4, 2

018






(C) GA causes inhibition of translocation of STAT3 to the nucleus. U266 cells

(2x106/mL) were incubated with or without 2.5 µM GA for 6 h and then analyzed for the

intracellular distribution of STAT3 by immunocytochemistry. (D) GA suppresses STAT3

DNA binding in a dose-dependent manner. U266 cells (2x106/mL) were treated with the

indicated concentrations of GA for 6 h and analyzed for nuclear STAT3 levels by EMSA

(left panel). GA suppresses STAT3 DNA binding in a time-dependent manner. U266

cells (2x106/mL) were treated with 2.5 µM GA for the indicated times and analyzed for

nuclear STAT3 levels by EMSA (right panel).

Figure 3. (A) GA down-regulates IL-6–induced phospho-STAT3. MM1.S cells (2 × 106)

were treated with IL-6 (10 ng/mL) for the indicated times. Whole-cell extracts were

prepared, and phospho-STAT3 level was detected by Western blot. The same blot was

stripped and reprobed with STAT3 antibody to verify equal protein loading. (B) MM1.S

cells (2 × 106) were treated with 2.5 μM GA for the indicated times and then stimulated

with IL-6 (10 ng/mL) for 15 min. Whole-cell extracts were then prepared and analyzed

for phospho-STAT3 by Western blotting. The same blot was stripped and reprobed with

STAT3 antibody to verify equal protein loading (lower panel).

Figure 4. (A) GA suppresses phospho-JAK1 expression. U266 cells (2x106/ml) were

treated with 2.5 μM GA for indicated time, after which whole-cell extracts were prepared

and 40 µg protein were resolved on 10% SDS-PAGE, electrotransferred onto

nitrocellulose membranes, and probed for phospho-JAK1 antibody. The same blots were

stripped and reprobed with JAK1 antibody to verify equal protein loading. (B) GA



Retrac

ted Sep

tembe

r 4, 2

018






suppresses expression of phospho-JAK2. U266 cells (2x106/ml) were treated with 2.5 μM

GA for indicated time, after which whole cell extracts were prepared. Western blotting

for phospho-JAK2 was performed. The same blots were stripped and reprobed with

JAK2 antibody to verify equal protein loading. (C) To determine the activity of JAK2, a

kinase assay was performed using GA (2.5 μM) treated whole-cell extract as described in

‘Materials and Methods'. Total protein level was determined by western bloting.

Figure 5. (A) Pervanadate reverses the phospho-STAT3 inhibitory effect of GA. U266

cells (2x106/ml) were treated with pervanadate and 2.5 µM GA for 6 h, after which

whole-cell extracts were prepared, and 40 µg protein extracts were resolved on 7.5%

SDS-PAGE gel, electrotransferred onto nitrocellulose membranes, and probed for

phospho-STAT3 and STAT3. (B) GA induces the expression of SHP-1 protein. U266

cells (2 x 106/mL) were treated with indicated concentrations of GA for 6 h, after which

whole-cell extracts were prepared and 40 µg proteins were resolved on 10% SDS-PAGE,

electrotransferred onto nitrocellulose membranes, and probed with SHP-1 antibody. The

same blots were stripped and reprobed with β-actin antibody to verify equal protein

loading. (C) Effect of SHP-1 knockdown on GA–induced expression of SHP-1. SCC4

cells (2 x 106/mL) were transfected with either SHP-1 siRNA or scrambled siRNA (50

nM). After 48 h, cells were treated with 2.5 µM GA for 6 h, and whole-cell extracts were

subjected to Western blot analysis for SHP-1. The same blots were stripped and reprobed

with β-actin antibody to verify equal protein loading (left panel). Transfection with SHP-

1 siRNA reverses GA-induced suppression of STAT3 activation. SCC4 cells (2 x

106/mL) were transfected with either SHP-1 siRNA or scrambled siRNA (50 nM). After



Retrac

ted Sep

tembe

r 4, 2

018






48 h, cells were treated with 2.5 µM GA for 6 h, and whole-cell extracts were subjected

to Western blot analysis for phosphorylated STAT3. The same blots were stripped and

reprobed with STAT3 antibody (right panel). (D) Knockdown of SHP-1 inhibited the

apoptotic effect of GA. SCC4 cells (1 x 105/mL) were transfected with either scrambled

or SHP-1–specific siRNA (50 nM). After 48 h, cells were treated with 50 µM GA for 24

h, and the percentage of apoptosis was analyzed by the live/dead assay.

Figure 6. GA suppresses STAT3-regulated proliferative, survival, and angiogenic gene

products. U266 cells (2 x 106/mL) were treated with 2.5 µM GA for the indicated time

intervals, after which whole cell extracts were prepared and 40 µg proteins resolved on

10% SDS-PAGE and probed against (A) c-IAP, survivin, Mcl-1, bcl-2, bcl-xl (B) cyclin

D1, VEGF, COX-2, and ICAM-1 antibody. The same blots were stripped and reprobed

with β-actin antibody to verify equal protein loading. (C) Schematic representation of

mechanism by which GA inhibits STAT3 activation and induces apoptosis.



Retrac

ted Sep

tembe

r 4, 2

018







Retrac

ted Sep

tembe

r 4, 2

018





Retraction

Retraction: Gambogic Acid Inhibits STAT3Phosphorylation through Activation ofProtein Tyrosine Phosphatase SHP-1:Potential Role in Proliferation andApoptosis

This article (1) has been retracted at the request of the editors. An internaljournal investigation determined that the pSTAT3 immunoblot in Fig. 5Cappears to have been inappropriately digitally manipulated. In addition, animage of the same field of cells was used to represent the effects of SHP-1siRNA under two experimental conditions (control and gambogic acidtreatments) in Fig. 5D. The original research records related to Fig. 5D werenot available during an institutional investigation.

A copy of this Retraction Notice was sent to the last known email addressesfor all four authors. Two authors (S. Prasad and B.B. Aggarwal) did not agreeto the retraction; the two remaining authors (M.K. Pandey and V.R. Yadav)did not respond.

Reference1. Prasad S, Pandey MK, Yadav VR, Aggarwal BB. Gambogic acid inhibits STAT3 phos-

phorylation through activation of protein tyrosine phosphatase SHP-1: potential rolein proliferation and apoptosis. Cancer Prev Res 2011;4:1084–94.

Published online August 21, 2018.doi: 10.1158/1940-6207.CAPR-18-0235�2018 American Association for Cancer Research.

CancerPreventionResearch

www.aacrjournals.org 593

http://crossmark.crossref.org/dialog/?doi=10.1158/1940-6207.CAPR-18-0235&domain=pdf&date_stamp=2018-8-21

Published OnlineFirst April 13, 2011.Cancer Prev Res Sahdeo Prasad, Manoj K. Pandey, Vivek R Yadav, et al. Role in Proliferation and ApoptosisActivation of Protein Tyrosine Phosphatase SHP-1: Potential Gambogic Acid Inhibits STAT3 Phosphorylation Through

Updated version

10.1158/1940-6207.CAPR-10-0340doi:

Access the most recent version of this article at:

Manuscript

Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been

E-mail alerts related to this article or journal.Sign up to receive free email-alerts

Subscriptions

Reprints and

[email protected] at

To order reprints of this article or to subscribe to the journal, contact the AACR Publications

Permissions

Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)

.40http://cancerpreventionresearch.aacrjournals.org/content/early/2011/04/12/1940-6207.CAPR-10-03To request permission to re-use all or part of this article, use this link



http://cancerpreventionresearch.aacrjournals.org/lookup/doi/10.1158/1940-6207.CAPR-10-0340

http://cancerpreventionresearch.aacrjournals.org/cgi/alerts

mailto:[email protected]

http://cancerpreventionresearch.aacrjournals.org/content/early/2011/04/12/1940-6207.CAPR-10-0340

http://cancerpreventionresearch.aacrjournals.org/content/early/2011/04/12/1940-6207.CAPR-10-0340


Sahdeo Prasad, Manoj K. Pandey, Vivek R. Yadav and Bharat ......Sahdeo Prasad, Manoj K. Pandey,...

Documents

Transcript of Sahdeo Prasad, Manoj K. Pandey, Vivek R. Yadav and Bharat ......Sahdeo Prasad, Manoj K. Pandey,...